material information disclosure

Class action lawsuit filed against $ENPH alleges securities fraud over channel inventory management and Clean Energy Credit disclosure failures. Deadline for lead plaintiff claims: April 20, 2026.

Apollo Global Management faces a securities class action lawsuit alleging leadership concealed Epstein communications. Investors with losses exceeding $100,000 must apply for lead plaintiff status by May 1, 2026.

Enphase Energy shareholders must file lead plaintiff applications by April 20, 2026 in a class action alleging disclosure failures regarding inventory management and tax credit impacts.

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant. Stock crashed 50% following misleading investor claims about approval prospects.

BellRing Brands faces securities fraud class action for failing to disclose inventory issues. Stock plummeted 52% after May and August 2025 negative announcements.

Trip.com faces securities fraud lawsuit after China's antitrust probe; stock plunged 19.4% with investors losing $12.90 per share initially.

Ultragenyx Pharmaceutical's stock plunged 42% after failing to disclose setrusumab Phase 3 trial failure, triggering securities litigation with April 6, 2026 lead plaintiff deadline.

uniQure faces securities lawsuit after FDA rejected AMT-130 approval pathway. Stock plummeted 49% following disclosure. Lead plaintiff deadline: April 13, 2026.

Apollo Global Management faces class action over alleged Epstein executive communications non-disclosure. Investors with $100,000+ losses must apply as lead plaintiffs by May 1, 2026.

Apollo Global Management faces securities class action lawsuit over alleged Epstein disclosure failures. Lead plaintiff deadline set for May 1, 2026.

$QURE plunged 49% after FDA rejected AMT-130 Phase I/II data for accelerated approval. Securities lawsuit filed; lead plaintiff deadline April 13, 2026.

Enphase Energy faces class action lawsuit over failure to disclose inventory management limitations and tax credit risks. Lead plaintiff deadline: April 20, 2026.

Class action lawsuit filed against Enphase Energy alleging securities fraud related to undisclosed channel inventory and tax credit impact concerns between April 2025 and October 2025.

uniQure stock plunges 49% after FDA rejects gene therapy data for AMT-130, triggering securities fraud class action lawsuit for investors trading September-October 2025.

Corcept Therapeutics stock plummeted 50% after FDA rejected lead drug relacorilant. Investors allege prior misleading statements about approval likelihood.

BellRing Brands faces securities fraud lawsuit after 52% stock decline tied to undisclosed inventory issues and weak guidance, with investor deadline March 23, 2026.

Ultragenyx faces securities lawsuit over delayed disclosure of failed Phase 3 trial. Investors must file lead plaintiff claims by April 6, 2026.

Corcept faces securities lawsuit after FDA rejected its drug candidate, causing 50% stock drop. Investors must apply by April 21 for class action lead plaintiff status.

uniQure faces class action lawsuit over failing to disclose FDA rejection of AMT-130 drug candidate, causing 49% stock decline. Lead plaintiff deadline: April 13, 2026.

uniQure faces securities fraud lawsuit after FDA rejected its drug candidate AMT-130, causing a 49% stock plunge. Plaintiffs allege the company failed to disclose material information to investors.